Monte Rosa Therapeutics Inc
GLUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$19.25
17.9% downside
Current Fair Value
17.9% downsideOvervalued by 17.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 1.56 |
| Outstanding Shares | 65,543,723 |
Return
| Return on Equity | -24.91% |
|---|---|
| Return on Assets | -17.65% |
| Return on Invested Capital | -22.60% |
Valuation & Multiples
| P/E Ratio | -12.39 |
|---|---|
| PEG | 6.35 |
| Price to Sales | - |
| Price to Book Ratio | 3.35 |
| Enterprise Value to Revenue | 32.89 |
| Enterprise Value to EBIT | -9.39 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$11.41 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$12.91 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.68% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.05%▼ 104.61% |
|---|---|
| Total Invested | $851,066▼ 99.94% |
| Investors Holding | 4▼ 191.00% |
ESG Score
No data
About Monte Rosa Therapeutics Inc
60 employees